Petrolatum-based compositions comprising cationic biocides
The disclosure provides stable formulations of cationic biocides that are primarily used in the treatment and prevention of infections. The disclosure is also concerned with processes for forming stable emulsions of cationic biocides and petrolatum.
1. A stable petrolatum-based composition comprising:
greater than about 80% by weight petrolatum;
a polar solvent; and
a cationic biocide, wherein the cationic biocide is selected from the group consisting of benzalkonium chloride, cetrimide, chlorhexidine, polihexanide biguanide, polyaminopropyl biguanide, and any combination thereof;
wherein the composition contains no emulsifier.
2. The composition of claim 1 , wherein the cationic biocide is a mixture of benzalkonium chloride and polihexanide biguanide.
3. The composition of claim 1 , wherein the polar solvent is water.
4. The composition according to claim 1 , wherein the polar solvent and the cationic biocide are dispersed in the petrolatum in the form of nanodroplets.
5. The composition according to claim 1 , wherein the polar antimicrobial ingredient comprises less than 1% by weight of the petrolatum-based composition.
6. The composition according to claim 1 , wherein the composition is greater than 90% by weight petrolatum.
7. A method for treating or preventing an infection in a subject, the process comprising applying the composition of claim 1 to the skin of a subject.
8. A wound dressing comprising a therapeutically effective amount of the composition according to claim 1 .
9. A suture comprising a therapeutically effective amount of the composition according to claim 1 .
10. A stable petrolatum-based composition consisting essentially of:
greater than about 80% by weight petrolatum;
a polar solvent; and
a cationic biocide, wherein the cationic biocide is selected from the group consisting of benzalkonium chloride, cetrimide, chlorhexidine, polihexanide biguanide, polyaminopropyl biguanide, and any combination thereof.
11. The composition of claim 10 , wherein the cationic biocide is a mixture of benzalkonium chloride and polihexanide biguanide.
12. The composition of claim 10 , wherein the polar solvent is water.
13. The composition of claim 10 , wherein the cationic biocide and polar solvent are dispersed in the petrolatum in the form of nanodroplets.
14. A method for treating or preventing an infection in a subject, the process comprising applying the composition of claim 10 to the skin of a subject.
15. A wound dressing comprising a therapeutically effective amount of the composition according to claim 10 .
16. A suture comprising a therapeutically effective amount of the composition according to claim 10 .
17. A process for preparing a petrolatum-based composition comprising petrolatum and a cationic biocide the process comprising:
a) dissolving the cationic biocide in a polar solvent to give a antimicrobial ingredient solution;
b) heating the petrolatum to a temperature sufficient to cause the petrolatum to melt to give a melted petrolatum and heating the antimicrobial ingredient solution to a temperature higher than the temperature of the melted petrolatum to give a heated antimicrobial ingredient solution;
c) mixing the melted petrolatum and the heated antimicrobial ingredient solution to give a melted mixture; and
d) cooling the melted mixture to give the petrolatum-based composition, wherein the composition comprises greater than 80% by weight petrolatum and contains no emulsifier.
18. The process of claim 17 , wherein the cationic biocide is selected from the group consisting of benzalkonium chloride, cetrimide, chlorhexidine, polihexanide biguanide, polyaminopropyl biguanide, and any combination thereof.
19. The process of claim 17 , wherein the heated antimicrobial ingredient solution has a temperature that is about 1° C. to about 5° C. higher than the temperature of the melted petrolatum.
20. The process of claim 19 , wherein the cationic biocide is a mixture of benzalkonium chloride and polihexanide biguanide, and wherein the solvent is water.
21. The process of claim 17 , wherein the cationic biocide maintains efficacy for at least 3 months when stored at 40° C.±2° C. and 75%±5% relative humidity.